Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-011 in Hepatocellular Carcinoma
NCT00966251Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2009
- Primary completion
- Jun 2011
- Countries
- 1
- Sponsor
- CureTech
- Modality
- Monoclonal Antibodies
- Drugs
- pidilizumab
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of pidilizumab in hepatocellular carcinoma (HCC), sponsored by CureTech. Primary endpoint: Safety and Tolerability of CT-011 at 12 months. Started Oct 2009; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CT-011
Experimental arm receiving CT-011
03
Who it enrols
Adult patients with histologically confirmed Primary Hepatocellular Carcinoma (Child-Pugh A, ECOG 0-1) who are not candidates for curative surgery, transplant, or TACE, and have no extrahepatic metastasis.
04
Endpoints
Primary
Safety and Tolerability of CT-011
Beyond the preview
Go deeper on NCT00966251.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00966251.